LEO Pharma
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING4
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| TRAPEDS 2 NCT06311682 |
P3 | Recruiting | Atopic Dermatitis | 195 | 2026-10-16 (+7 mo) |
| Delgocitinib cream NCT07013201 |
P2 | Recruiting | Palmoplantar Pustulosis | 135 | 2027-06-04 (+6 mo) |
| Spesolimab NCT03886246 |
P2 | Active, not recruiting | Generalized Pustular Psoriasis | 131 | 2027-09-30 (+20 mo) |
| Spesolimab NCT06624670 |
P3 | Recruiting | Pyoderma Gangrenosum | 90 | 2027-11-12 (+10 mo) |
| DELTA CARE 1 NCT07335588 |
P3 | Recruiting | Lichen Sclerosus | 552 | 2028-03-10 |